Tina Liu

Tina Liu is a distinguished alumna and former entrepreneur-in-residence at Harvard University. She received her M.B.A. with Distinction from Harvard Business School and later served as an entrepreneur-in-residence at the Wyss Institute from 2017 to 2019.12

Professional Achievements

During her time at the Wyss Institute, Tina Liu worked alongside Founding Core Faculty member George Church and Research Scientist Ying Kai Chan to develop safer and more efficacious gene therapies.1 Their research focused on dampening innate immune responses against adeno-associated virus (AAV), which is the most commonly used gene therapy vector.2

Recognition

Tina Liu's contributions to the field of gene therapy have earned her significant recognition:

• She was honored as a Gold Winner of the Women World Awards in the category of Female Executive of the Year.12
• This award acknowledged her work in developing novel technology to enhance the safety and effectiveness of gene therapies.1

Current Endeavors

Following her tenure at the Wyss Institute, Tina Liu has been working to commercialize the technology she developed with Ying Kai Chan through a start-up company.2 This venture continues the Wyss Institute's tradition of translating groundbreaking scientific research into successful businesses.1

Background

Prior to her work at Harvard, Tina Liu had a successful career in finance:

• She worked as an investment banker at Morgan Stanley.1
• She also held a position as a private equity investor at TPG Capital.1

Tina Liu's unique combination of business acumen and scientific expertise has positioned her as a notable figure in the biotechnology entrepreneurship space, bridging the gap between academic research and commercial applications in gene therapy.